Insider · CIK 0001653262
Raymond Prudo-Chlebosz
Files at AKTX (Akari Therapeutics Plc). First filing -, latest -.
Raymond Prudo-Chlebosz files SEC Form 4 as director at AKTX (Akari Therapeutics Plc). No open-market trade is on file; the transactions below are grants, exercises and other rows that carry no view on the price.
A track record needs three past buys with six months of prices behind them; Raymond Prudo-Chlebosz has 0, so none is measured yet.
Signals
This insider’s open-market buys and sells, scored.
Transactions
Every row this insider has filed, 11 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Dec 16, 2025 | AKTX Akari Therapeutics Plc | POpen-market purchase Warrants to purchase American Depositary Shares ("ADRs")derivative | +618,658 | - | - | 618,658 | Dec 18, 2025 |
| Dec 16, 2025 | AKTX Akari Therapeutics Plc | POpen-market purchase Pre-Funded Warrants to purchase ADRsderivative | +618,658 | $0.40 | $250k | 618,658 | Dec 18, 2025 |
| Dec 16, 2025 | AKTX Akari Therapeutics Plc | POpen-market purchase Warrants to purchase ADRsderivative | +386,661 | - | - | 386,661 | Dec 18, 2025 |
| Dec 16, 2025 | AKTX Akari Therapeutics Plc | POpen-market purchase Pre-Funded Warrants to purchase ADRsderivative | +386,661 | $0.40 | $156k | 386,661 | Dec 18, 2025 |
| Mar 20, 2025 | AKTX Akari Therapeutics Plc | AGrant or award Stock Option (Right to Buy)derivative | +175,000 | $0.00 | $0 | 175,000 | Mar 24, 2025 |
| Mar 20, 2025 | AKTX Akari Therapeutics Plc | AGrant or award Stock Option (Right to Buy)derivative | +225,000 | $0.00 | $0 | 225,000 | Mar 24, 2025 |
| Mar 6, 2025 | AKTX Akari Therapeutics Plc | AGrant or award American Depositary Shares representing Ordinary Shares | +446,428 | $1.12 | $500k | 2,484,990 | Mar 10, 2025 |
| Mar 6, 2025 | AKTX Akari Therapeutics Plc | AGrant or award Series A Warrants (Right to Buy)derivative | +446,428 | $1.12 | $500k | 446,428 | Mar 10, 2025 |
| Mar 6, 2025 | AKTX Akari Therapeutics Plc | AGrant or award Series B Warrants (Right to Buy)derivative | +446,428 | $1.12 | $500k | 446,428 | Mar 10, 2025 |
| Dec 2, 2024 | AKTX Akari Therapeutics Plc | AGrant or award Ordinary Shares, par value $0.0001 per share | +419,286,000 | $0.00 | $503k | 4,077,124,600 | Dec 3, 2024 |
| Dec 2, 2024 | AKTX Akari Therapeutics Plc | AGrant or award Warrants (Right to Buy)derivative | +419,286,000 | $0.00 | $503k | 419,286,000 | Dec 3, 2024 |
Questions about Raymond Prudo-Chlebosz
Answered from the filings on this page, as of the latest one.
Is Raymond Prudo-Chlebosz buying or selling?
Raymond Prudo-Chlebosz has no open-market buy or sell on SEC Form 4; the filings on record are grants, exercises and other transactions.
How did Raymond Prudo-Chlebosz's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Raymond Prudo-Chlebosz has 0.
Where does Raymond Prudo-Chlebosz file Form 4?
Raymond Prudo-Chlebosz has filed Form 4 at AKTX (Akari Therapeutics Plc). A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.